Inhaled fluticasone reduces bronchial responsiveness and airway inflammation in cats with mild chronic bronchitis.
This study investigated the effect of inhaled fluticasone on lower airway inflammation and bronchial responsiveness (BR) to inhaled carbachol in cats with very mild, chronic bronchitis (n = 5) that were compared with healthy cats serving as controls (n = 6). Chest radiographs, BR tests performed non-invasively by barometric whole body plethysmography (BWBP) and bronchoalveolar lavage (BAL) were performed before and after treatment. BR was quantified by calculating the concentration of carbachol inducing bronchoconstriction (C-Penh300%), defined as a 300% increase of baseline Penh, an index of bronchoconstriction obtained by BWBP. BAL fluid was analyzed cytologically and the oxidant marker 8-iso-PGF2alpha was determined. At test 1, healthy cats and cats with bronchitis were untreated, whereas for test 2 inhalant fluticasone (250 microg once daily) was administrated for 2 consecutive weeks to cats with bronchitis. Control cats remained untreated. Inhaled fluticasone induced a significant increase in C-Penh300% and a significant decrease of BAL fluid total cells, macrophages, neutrophils and 8-iso-PGF2alpha in cats with bronchitis, whilst untreated control cats did not show significant changes over time. This study shows that a 2-week fluticasone treatment significantly reduced lower airway inflammation in very mild bronchitis. BR could be successfully monitored in cats using BWPB and decreased significantly in response to inhaled fluticasone. 8-Iso-PGF2alpha in BAL fluid was responsive to treatment and appeared as a sensitive biomarker of lower airway inflammation in cats.
Kirschvink
Nathalie
N
Department for Functional Sciences B41, Faculty of Veterinary Medicine, University of Liège, 4000 Liège, Belgium. kirschvink@fundp.ac.be
Leemans
Jérôme
J
Delvaux
François
F
Snaps
Frédéric
F
Jaspart
Séverine
S
Evrard
Brigitte
B
Delattre
Luc
L
Cambier
Carole
C
Clercx
Cécile
C
Gustin
Pascal
P
D000280:Administration, Inhalation; D000730:Androstadienes / Q000008:administration & dosage*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D029481:Bronchitis, Chronic / Q000188:drug therapy / Q000662:veterinary*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D016022:Case-Control Studies; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D005260:Female; D000068298:Fluticasone; D008297:Male; D010991:Plethysmography / Q000662:veterinary; D016896:Treatment Outcome
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D000068298:Fluticasone